Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin

Acta Neurologica Scandinavica

Volumn 124, Issue SUPPL. 192, 2011, Pages 48-56

  Sergott, R C ^a   Westall, C A ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Electroretinogram; Infantile spasms; Perimetry; Refractory epilepsy; Review; Vigabatrin; Visual field defect; Visual field testing

Indexed keywords

VIGABATRIN; ANTICONVULSIVE AGENT; GABAERGIC RECEPTOR AFFECTING AGENT;

ADULT; ARTICLE; COLOR VISION; COMPLEX PARTIAL SEIZURE; DAILY LIFE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; EARLY DIAGNOSIS; ELECTROPHYSIOLOGY; ELECTRORETINOGRAPHY; EVOKED VISUAL RESPONSE; EYE EXAMINATION; HUMAN; INFANT; INFANTILE SPASM; MONOTHERAPY; OSCILLATORY POTENTIAL; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PERIMETRY; QUANTITATIVE ANALYSIS; RETINA DEGENERATION; RETINA DYSTROPHY; RETINA INJURY; RISK ASSESSMENT; RISK FACTOR; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT DURATION; VISUAL ACUITY; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; VISUAL STIMULATION; VISUAL SYSTEM EXAMINATION; VISUAL SYSTEM FUNCTION; CHEMICALLY INDUCED DISORDER; FOCAL EPILEPSY; REVIEW; VISUAL DISORDER;

ADULT; ANTICONVULSANTS; ELECTRORETINOGRAPHY; EPILEPSIES, PARTIAL; GABA AGENTS; HUMANS; INFANT; SPASMS, INFANTILE; VIGABATRIN; VISION DISORDERS; VISUAL FIELD TESTS;

EID: 80855133032     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2011.01600.x     Document Type: Article

References (34)

1. SABRIL® [prescribing information]. Deerfield, IL: Lundbeck Inc., 2010.
2. Ben-Menachem E, Sander JW. Vigabatrin therapy for refractory complex partial seizures: review of major European trials. Acta Neurol Scand 2011;124(Suppl. 192):16-28.
3. Carmant L. Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing. Acta Neurol Scand 2011;124(Suppl. 192):36-47.
4. Faught RE. Vigabatrin therapy for refractory complex partial seizures: review of major US trials. Acta Neurol Scand 2011;124(Suppl. 192):29-35.
5. Sergott RC. Recommendations for visual evaluations of patients treated with vigabatrin. Curr Opin Ophthalmol 2010;21:442-6.
6. Sergott RC, Wheless JW, Smith MC et al. Evidence-based review of recommendations for visual function testing in patients treated with vigabatrin. Neuro-opthalmology 2010;34:20-35.
7. American Academy of Ophthalmology. The patient with decreased vision: evaluation. In: American Academy of Ophthalmology, ed. Neuro-ophthalmology, section 5, basic and clinical science course. San Francisco: American Academy of Ophthalmology, 2009;91-110.
8. Cohen S, Kawasaki A. Introduction to formal visual field testing: Goldmann and Humphrey perimetry. J Ophthalmic Nurs Technol 1999;18:7-11.
9. Kälviäinen R, Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 2001;15:217-30.
10. Keltner JL, Johnson CA, Quigg JM et al. Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Arch Ophthalmol 2000;118:1187-94.
11. Centofanti M, Fogagnola P, Oddone F. Learning effect of Humphrey matrix frequency doubling technology perimetry in patients with ocular hypertension. J Glaucoma 2008;17:436-41.
12. American Academy of Ophthalmology. Retinal physiology and psychophysics. In: American Academy of Ophthalmology, ed. Retina and vitreous, section 12, basic and clinical science course. San Francisco: American Academy of Ophthalmology, 2010;33-53.
13. Westall C, Kriss A, Thompson D. Pediatric visual electrophysiology. In: Wright K, ed. Pediatric ophthalmology and strabismus, 3rd edn. Oxford University Press, 2012; in press.
14. Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M. ISCEV Standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol 2009;118:69-77.
15. Fulton AB, Hansen RM, Westall CA. Development of ERG responses: the ISCEV rod, maximal and cone responses in normal subjects. Doc Ophthalmol 2003;107:235-41.
16. Westall CA, Panton CM, Levin AV. Time courses for maturation of electroretinogram responses from infancy to adulthood. Doc Ophthalmol 1999;96:355-79.
17. American Academy of Ophthalmology. Diagnostic approach to retinal disease. In: American academy of ophthalmology, ed. Retina and vitreous, section 12, basic and clinical science course. San Francisco: American Academy of Ophthalmology, 2010;19-31.
18. ® (vigabatrin): an open-label, Phase IV study. Poster 1.294. Presented at the 64th annual meeting of the American Epilepsy Society; December 3-7, 2010; San Antonio, TX.
19. Frisén L, Malmgren K. Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand 2003;81:466-73.
20. Buncic JR, Westall CA, Panton CM, Munn JR, MacKeen LD, Logan WJ. Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 2004;111:1935-42.
21. Plant GT, Sergott RC. Understanding and interpreting vision safety issues with vigabatrin 2011;124(Suppl. 192):57-71.
22. Malmgren K, Ben-Menachem E, Frisén L. Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia 2001;42:609-15.
23. Frisén L. Vigabatrin-associated loss of vision: rarebit perimetry illuminates the dose-damage relationship. Acta Ophthalmol Scand 2004;82:54-8.
24. McCoy B, Wright T, Weiss S, Go C, Westall CA. Electroretinogram changes in a pediatric population with epilepsy: is vigabatrin acting alone? J Child Neurol 2011;26:729-33.
25. Morong S, Westall CA, Nobile R et al. Longitudinal changes in photopic OPs occurring with vigabatrin treatment. Doc Ophthalmol 2003;107:289-97.
26. Westall CA, Logan WJ, Smith K, Buncic JR, Panton CM, Abdolell M. The Hospital for Sick Children, Toronto, Longitudinal ERG study of children on vigabatrin. Doc Ophthalmol 2002;104:133-49.
27. Westall CA, Nobile R, Morong S, Buncic JR, Logan WJ, Panton CM. Changes in the electroretinogram resulting from discontinuation of vigabatrin in children. Doc Ophthalmol 2003;107:299-309.
28. Harding GF, Robertson K, Spencer EL, Holliday I. Vigabatrin: its effect on the electrophysiology of vision. Doc Ophthalmol 2002;104:213-29.
29. Harding GF, Wild JM, Robertson KA et al. Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction. Epilepsia 2000;41:1420-31.
30. Harding GF, Wild JM, Robertson KA, Rietbrock S, Martinez C. Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. Neurology 2000;55:347-52.
31. Spencer EL, Harding GF. Examining visual field defects in the paediatric population exposed to vigabatrin. Doc Ophthalmol 2003;107:281-7.
32. Hammoudi DS, Lee SSF, Madison A et al. Reduced visual function associated with infantile spasms in children on vigabatrin therapy. Invest Ophthalmol Vis Sci 2005;46:514-20.
33. Mirabella G, Morong S, Buncic JR et al. Contrast sensitivity is reduced in children with infantile spasms. Invest Ophthalomol Vis Sci 2007;48:3610-5.
34. Pellock JM. Balancing the clinical benefit of vigabatrin with its associated risk of vision loss. Acta Neurol Scand 2011;124(Suppl. 192):83-91.